Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
Funding Rounds (2) - $3.8MUpdate
University of Cambridge Enterprise, also known as Cambridge Enterprise Seed Funds, consisting of...
Babraham Research Campus
Cambridge, CB22 3AT